Economic analyses in clinical trials for cooperative groups: Operational considerations

Cancer Investigation

Volumn 15, Issue 5, 1997, Pages 448-453

  Bennett, Charles L ^a   Waters, Teresa M ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESEARCH; CLINICAL PROTOCOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEALTH ECONOMICS; HUMAN; MULTICENTER STUDY; PRIORITY JOURNAL; RESOURCE ALLOCATION; TREATMENT OUTCOME;

EID: 0030882072     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709047584     Document Type: Article

References (27)

1. Smith TJ, Hillner BE, Desch CE: Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis. JNCI 85(18): 1460-1474, 1993.
2. Schulman KA, Yabroff RK: Measuring the cost-effectiveness of cancer care. Oncology 9:523-538, 1995.
3. Jaakimainen I, Goodwin PJ, Pater J, Warde P, Murray N, Rapp E: Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J Clin Oncol 8:1301-1309, 1990.
4. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia: Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: A randomized, controlled clinical trial. N Engl J Med 319:902-907, 1988.
5. Kennedy BJ: Excessive test costs in clinical research protocols. J Cancer Ed 6:93-97, 1991.
6. Eisenberg JM, Glick H, Koffer H: Pharmacoeconomics:Economic evaluation of pharmaceuticals. In: Pharmacoepidemiology, edited by B Strom, New York, Churchill Livingstone, 1989.
7. Welch HG, Larson EB: Cost-effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 321:807-812, 1989.
8. Ray WA, Griffin MR, Avorn J: Evaluating drugs after their approval for clinical use. N Engl J Med 329:2029-2032, 1993.
9. Gulati SC, Bennett CL: Granulocyte-macrophage colony stimulating factor as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med 116:177-182, 1992.
10. Welch HG: Valuing clinical strategies early in their development. Ann Intern Med 116:263-264, 1992.
11. Drummond MF, Davies L: Economic analysis alongside clinical trials: Revisiting the methodologies issues. Int J Tech Assess Health Care 7:561-563, 1991.
12. Haan GHG, Rutten FFH: Economic appraisal, health service planning, and budgetary management for the health technologies. In: Economic Appraisal of Health Technology in the European Community, edited by MF Drummond, Oxford, UK, Oxford University Press, 1987, pp 135-146.
13. Cancer and Leukemia Group B: Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study. Protocol CALGB-9334, 1994.
14. Eastern Cooperative Oncology Group: A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Colectomy Versus Open Colectomy for Colon Cancer. Protocol ECOG-E7293, 1995.
15. Children's Cancer Group: A Study of Minimally Invasive Surgery of the Chest in Children with Cancer. Protocol CCG-S942, 1995.
16. Pediatric Oncology Group: Assessment of the Role of Minimal Access Surgery in the Treatment of Childhood Cancer: Intergroup Laparoscopy Protocol. Protocol POG-9485, 1995.
17. Buxton MJ: National Wilms' Tumor Study: Economic perspective. Monogr Natl Cancer Inst 19:27-29, 1995.
18. Green DM, Breslow NE, Evans I, Moksness J, Finklestein JZ, Evans AE, D'Angio GJ: Relationship between dose schedule and charges for treatment on National Wilms' Tumor Study-4. A report from the National Wilms' Tumor Study Group. Monogr Natl Cancer Inst 19:21-25, 1995.
19. Bennett CL, Armitage JL, LeSage S, Gulati S, Armitage JO, Gorin C: Economic analyses of clinical trials in cancer: Are they helpful to policy makers? Stem Cells 12:424-429, 1994.
20. Bennett CL, Smith TJ, George SL, Hillner BE, Fleishman S, Neill HB: Free-riding and the prisoner's dilemma: Problems in funding economic analyses of phase III cancer clinical trials. J Clin Oncol 13:2457-2463, 1995.
21. Bennett CL, Armitage JL, Buchner D, Gulati S: Economic analysis in phase III clinical trials. Cancer Invest 12:336-342, 1994.
22. Drummond MF, Davies L: Economic analysis alongside clinical trials: Revisiting the methodologies issues. Int J Tech Assess Health Care 7:561-563, 1991.
23. Drummond MF, Stoddart GL: (9). Economic analysis and clinical trial. Controlled Clin Trials 5:115-128, 1984.
24. Bennett CL, Armitage JL, Buchner D, Gulati S: Economic analysis in phase III clinical cancer trials. Cancer Invest 12:336-342, 1994.
25. Finkler SA: The distinction between cost and charges. Ann Intern Med 96:102-109, 1982.
26. Bennett CL, George SL, Vose JM, et al: Granulocyte macrophage colony stimulating factor (GM-CSF) as adjunct therapy in relapsed lymphoid malignancy: Economic analyses of phase III clinical trials. Stem Cells 13:414-420, 1995.
27. Hillman AL, Eisenberg JM, Pauly MV, Bloome BS, Glick K, Kinosian B, Schwartz JS: Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 324:1362-1365, 1991.